Brinker Capital’s Viking Therapeutics VKTX Stock Holding History

Brinker Capital’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$229K	Buy	31,712 +1,811	+6%	+$12K	0.01%	880
2020 Q1	$140K	Buy	29,901 +3,028	+11%	+$18.6K	0.01%	883
2019 Q4	$216K	Sell	26,873 -5,799	-18%	-$42.3K	0.01%	919
2019 Q3	$225K	Buy	32,672 +2,544	+8%	+$18.9K	0.01%	894
2019 Q2	$250K	Sell	30,128 -1,122	-4%	-$9.59K	0.01%	854
2019 Q1	$311K	Buy	31,250 +9,230	+42%	+$77.3K	0.01%	799
2018 Q4	$168K	Buy	+22,020	New	+$263K	0.01%	842

Other funds holding VKTX

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Brinker Capital's VKTX Position: Q2 2020 in Review

Brinker Capital increased its Viking Therapeutics (VKTX) stake by 6.1% in Q2 2020, buying an estimated $12K and bringing the position to 31,712 shares worth $229K. The position accounts for 0.01% of the portfolio, ranked #880.

Brinker Capital first reported a position in VKTX in Q4 2018 and has held it in 7 quarters since. The position peaked at $311K in Q1 2019. 138 funds tracked by Wall St. Rank hold VKTX as of Q2 2020.

Brinker Capital held 31,712 shares of Viking Therapeutics worth $229K as of Q2 2020.
Brinker Capital bought 1,811 Viking Therapeutics shares in Q2 2020, an estimated $12K.
Viking Therapeutics made up 0.01% of Brinker Capital's portfolio in Q2 2020, its #880 holding.
Brinker Capital first reported a position in Viking Therapeutics in Q4 2018 and has held it in 7 quarters since.
Brinker Capital's Viking Therapeutics position peaked at $311K in Q1 2019.
138 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2020.

Based on Brinker Capital's 13F filing for Q2 2020, filed 30 Jul 2020.